| Case No | EPF at time of scan | Clinical diagnosis | Neuropathological diagnosis | Braak stage | Neocortical NFT stage* | CERAD score | AD diagnosis by CERAD criteria | AD diagnosis by NIA-RI criteria | Category of LB pathology by Consensus criteria - 2003 | Probability: dementia due to LB pathology by Consensus criteria - 2005 |
| 1 | – | AD | Mixed DLB, AD and HiScl | 5 | Moderate | Moderate | Probable | NAp | Neocortical | Intermediate |
| 2 | + | DLB | DLB | 0 | None | None | Normal-1c | None | Neocortical | High |
| 3 | + | DLB | DLB | 3 | None | None | Normal-1c | NAp | Neocortical | High |
| 4 | + | DLB | Mixed DLB and AD in MTL and SVD | 4 | NS | Moderate | Probable | Intermediate | Neocortical – severe | High |
| 5 | + | CBD | Mixed DLB and AD | 6 | Significant | Frequent | Definite | High likelihood | Neocortical | Intermediate |
| 6 | – | DLB | DLB | 2 | None | Sparse | Possible | Low likelihood | Neocortical | High |
| 7 | + | DLB | DLB and focal vascular pathology | 2 | None | None | Normal-1c | None | Neocortical | High |
| 8 | + | DLB | DLB | 1 | NS | none | Normal-1c | NAp | Neocortical – severe | High |
| 9 | – | AD | AD and focal SVD and severe Purkinje cell loss | 6 | Significant | Frequent | Definite | High likelihood | None | None |
| 10 | – | AD | AD and focal vasculopathy and occipital microinfarct | 5 | Moderate | Frequent | Definite | High likelihood | None | None |
| 11 | + | DLB | Mixed AD and CAA and haemorrhagic infarcts | 5 | Moderate | Frequent | Definite | High likelihood | None | None |
| 12 | – | DLB | AD and mild SVD | 6 | Significant | Frequent | Definite | High likelihood | None | None |
| 13 | + | DLB | CBD variant - non-tau balloon cell degeneration and subcortical tangle disease | 2 | None | Moderate | Probable | NAp | None | None |
| 14 | + | DLB | AD | 5 | ? | Frequent | Definite | High likelihood | None | None |
| 15 | – | AD | Minimal neuropathology: focal SVD and mild LB pathology and focal cortical lesions | 1 | None | None | Normal-1c | NAp | Brainstem | Low |
| 16 | – | AD | AD and HiScl and focal SVD | 6 | Significant | Frequent | Definite | High likelihood | None | None |
| 17 | + | DLB | FTLD (DLDH) and HiScl and nigral degeneration | 0 | None | None | Normal-1c | None | None | None |
| 18 | – | DLB | AD | 5 | Significant | Frequent | Definite | High likelihood | None | None |
| 19 | + | DLB | Mixed AD and CAA and focal vascular pathology | 6 | Significant | Moderate | Probable | NAp | None | None |
| 20 | – | AD | Mixed AD and SVD and multiple microinfarcts | 5 | Moderate | Frequent | Definite | High likelihood | None | None |
AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CBD, cortico-basal degeneration; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; DLDH, dementia lacking distinctive histology; DLB, dementia with Lewy bodies; EPF, extrapyramidal features; FTLD, frontotemporal lobar degeneration; HiScl, hippocampal sclerosis; LB, Lewy body; MTL, medial temporal lobe; NAp, not applicable; NFT, neurofibrillary tangle; NIA-RI, National Institute on Aging and Reagan Institute; NS, not significant; SVD, small vessel disease.
*Newcastle and Helsinki criteria.